Glutamate enrichment as new diagnostic opportunity in breast cancer

International Journal of Cancer

Volumn 136, Issue 7, 2015, Pages 1619-1628

  Budczies, Jan ^a,b   Pfitzner, Berit M ^a   Györffy, Balazs ^c,d   Winzer, Klaus Jürgen ^a   Radke, Cornelia ^e   Dietel, Manfred ^a,b   Fiehn, Oliver ^f   Denkert, Carsten ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e German Red Cross Hospital   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Glutamate; Glutamine; Metabolomics; PPAR signaling

Indexed keywords

BIOLOGICAL MARKER; GLUTAMIC ACID; GLUTAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ESTROGEN RECEPTOR;

AMINO ACID METABOLISM; ANALYTICAL PARAMETERS; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER TISSUE; CONTROLLED STUDY; GENE EXPRESSION; GENOME ANALYSIS; GLUTAMATE TO GLUTAMINE RATIO; GLUTAMINE METABOLISM; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASS FRAGMENTOGRAPHY; METABOLOMICS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TIME OF FLIGHT MASS SPECTROMETRY; BREAST NEOPLASMS; CANCER STAGING; CASE CONTROL STUDY; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; LYMPH NODE METASTASIS; METABOLISM;

BIOLOGICAL MARKERS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GLUTAMIC ACID; GLUTAMINE; HUMANS; LYMPHATIC METASTASIS; METABOLOMICS; NEOPLASM GRADING; NEOPLASM STAGING; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROGNOSIS; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84920945940     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29152     Document Type: Article

References (36)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Schulze A, Harris AL. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012;491:364-73.
3. Tennant DA, Durán RV, Boulahbel H, Gottlieb E. Metabolic transformation in cancer. Carcinogenesis 2009;30:1269-80.
4. Tennant DA, Durán RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010;10:267-77.
5. Warburg O, Posener K, Negelein E. Über den Stoffwechsel der Tumoren. Biochem Z 1924;152:319-44.
6. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927;8:519-30.
7. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007;104:19345-50.
8. Lu W, Pelicano H, Huang P. Cancer metabolism: Is glutamine sweeter than glucose? Cancer Cell 2010;18:199-200.
9. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 2011;27:441-64.
10. Fan J, Kamphorst JJ, Mathew R, et al. Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol 2013;9:712.
11. Eagle H. Nutrition needs of mammalian cells in tissue culture. Science 1955;122:501-14.
12. Yang L, Moss T, Mangala LS, et al. Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol 2014;10:728.
13. Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a kras-regulated metabolic pathway. Nature 2013;496:101-5.
14. Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest 2013;123:3678-84.
15. Lukey MJ, Wilson KF, Cerione RA. Therapeutic strategies impacting cancer cell glutamine metabolism. Future Med Chem 2013;5:1685-700.
16. Ahluwalia GS, Grem JL, Hao Z, et al. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther 1990;46:243-71.
17. James MO, Smith RL, Williams RT, et al. The conjugation of phenylacetic acid in man, subhuman primates and some non-primate species. Proc R Soc Lond B Biol Sci 1972;182:25-35.
18. Chang SM, Kuhn JG, Robins HI, et al. Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American brain tumor consortium report. J Clin Oncol 1999;17:984-90.
19. Timmerman LA, Holton T, Yuneva M, et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 2013;24:450-65.
20. Robinson MM, McBryant SJ, Tsukamoto T, et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J 2007;406:407-14.
21. Wang J, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010;18:207-19.
22. Wilson KF, Erickson JW, Antonyak MA, et al. Rho GTpases and their roles in cancer metabolism. Trends Mol Med 2013;19:74-82.
23. Gross MI, Demo SD, Dennison JB, et al. Antitumor activity of the glutaminase inhibitor cb-839 in triple-negative breast cancer. Mol Cancer Ther 2014;13:890-901.
24. Budczies J, Denkert C, Müller BM, et al. Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue-a GC-TOFMS based metabolomics study. BMC Genomics 2012;13:334.
25. Budczies J, Brockmöller SF, Müller BM, et al. Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism. J Proteomics 2013;94:279-88.
26. Budczies J, Kosztyla D, von Törne C, et al. Cancerclass: an R package for development and validation of diagnostic tests from high-dimensional molecular data. J Stat Software 2014;59:1-19.
27. Kanehisa M, Goto S, Sato Y, et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 2014;42:D199-205.
28. Denkert C, Budczies J, Weichert W, et al. Metabolite profiling of human colon carcinoma - deregulation of TCA cycle and amino acid turnover. Mol Cancer 2008;7:72.
29. Denkert C, Budczies J, Kind T, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006;66:10795-804.
30. Denkert C, Bucher E, Hilvo M, et al. Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Med 2012;4:37.
31. Terunuma A, Putluri N, Mishra P, et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest 2014;124:398-412.
32. Petersen A, Krumsiek J, Wägele B, et al. On the hypothesis-free testing of metabolite ratios in genome-wide and metabolome-wide association studies. BMC Bioinformatics 2012;13:120.
33. Balss J, Pusch S, Beck A, et al. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate. Acta Neuropathol 2012;124:883-91.
34. Sahm F, Capper D, Pusch S, et al. Detection of 2-hydroxyglutarate in formalin-fixed paraffin-embedded glioma specimens by gas chromatography/mass spectrometry. Brain Pathol 2012;22:26-31.
35. Pérez-de la Mora M, Méndez-Franco J, Salceda R, et al. A glutamate dehydrogenase-based method for the assay of L-glutamic acid: formation of pyridine nucleotide fluorescent derivatives. Anal Biochem 1989;180:248-52.
36. Dong J. Anticancer activities of PPARg in breast cancer are context-dependent. Am J Pathol 2013;182:1972-5.